Powered by HealthTechMovers.com
We added 4 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Roivant Sciences Ltd., ROIV
Summary: Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.
- Last Price: $11.45
- Price Change: $0.13, 1.15%
- Yearly Gain: 28.65%
- Market Cap: $9.20B
- P/E Ratio: -7.79
Here are 3rd party ratings for ROIV:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 35% (87 out of 250)
What is the sentiment on the street regarding Roivant Sciences Ltd. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus: {Blogger Consensus}
- Media Buzz: Sell
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in ROIV or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on ROIV before you decide to make any investment.
Click here for chart >>
Edgewise Therapeutics, Inc., EWTX
Summary: Edgewise Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Edgewise Therapeutics Inc. is based in Boulder, United States.
- Last Price: $18.32
- Price Change: $0.38, 2.12%
- Yearly Gain: 83.38%
- Market Cap: $1.56B
- P/E Ratio: -13.09
Here are 3rd party ratings for EWTX:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 35% (87 out of 250)
What is the sentiment on the street regarding Edgewise Therapeutics, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus: {Blogger Consensus}
- Media Buzz: Neutral
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: High Risk
If you are interested in EWTX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on EWTX before you decide to make any investment.
Click here for chart >>
Humacyte, Inc., HUMA
Summary: Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C.
- Last Price: $4.46
- Price Change: $0.26, 6.19%
- Yearly Gain: 39.81%
- Market Cap: $461.94M
- P/E Ratio: -5.13
Here are 3rd party ratings for HUMA:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 35% (87 out of 250)
What is the sentiment on the street regarding Humacyte, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus: {Blogger Consensus}
- Media Buzz: Neutral
- Insider Signal: Buying
- Investor Sentiment: Negative
- Hedge Fund signal: High Risk
If you are interested in HUMA or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on HUMA before you decide to make any investment.
Click here for chart >>
Repare Therapeutics Inc., RPTX
Summary: Repare Therapeutics Inc. is an oncology company. It utilizes genome-wide, CRISPR-enabled SNIPRx(R) platform to discover and develop targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's product pipeline includes RP-3500, which is in clinical stage. Repare Therapeutics Inc. is based in St-Laurent, Canada.
- Last Price: $6.95
- Price Change: $0.14, 2.06%
- Yearly Gain: -39.72%
- Market Cap: $292.80M
- P/E Ratio: -3.01
Here are 3rd party ratings for RPTX:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Buy, Top 35% (87 out of 250)
What is the sentiment on the street regarding Repare Therapeutics Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus: {Blogger Consensus}
- Media Buzz: Neutral
- Insider Signal: Buying
- Investor Sentiment: Negative
- Hedge Fund signal: High Risk
If you are interested in RPTX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on RPTX before you decide to make any investment.
Click here for chart >>
Thanks for reading!